Premium
Sleep‐disordered breathing in cystic fibrosis
Author(s) -
Jagpal Sugeet K.,
Jobanputra Aesha M.,
Ahmed Omar H.,
Santiago Teodoro V.,
Ramagopal Maya
Publication year - 2021
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25028
Subject(s) - medicine , cystic fibrosis , hypoxemia , comorbidity , intensive care medicine , obstructive sleep apnea , population , sleep apnea , quality of life (healthcare) , breathing , hypoventilation , disease , pediatrics , physical therapy , respiratory system , psychiatry , nursing , environmental health
Sleep‐disordered breathing (SDB) is an under recognized comorbidity in the cystic fibrosis (CF) population across the lifespan. Nocturnal hypoxemia, obstructive sleep apnea, and nocturnal hypoventilation are respiratory abnormalities that occur commonly during sleep in patients with lung disease, and have deleterious consequences to the quality of life in people with CF. Effective screening for these abnormalities is needed to allow for timely initiation of treatment, which has been reported to be efficacious. Lack of treatment leads to worsened pulmonary, cardiovascular, and metabolic outcomes in patients. In this review, we give an overview of SDB for the CF clinician, including prevalence, treatment, and suggestions for future research. We strongly encourage the CF community to incorporate evaluation for SDB in CF clinical care so that outcomes for the subset of the CF patients with comorbid SDB improve.